Pui Ying Chan - Concepedia

Author

Pui Ying Chan

Queen Mary University of London ORCID

Also Known As

P. Chan, P.Y. Chan, Pui Ying Chan

Publications

636

Citations

H-Index

Concepts

All Affiliations

Queen Mary University of London St Bartholomew's Hospital University College London Barts Health NHS Trust Moorfields Eye Hospital

About

Pui Ying Chan is an author at Queen Mary University of London specializing in tumor microenvironment, radiation oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	1	1	13
2	Immunology	1	1	13
3	Pathology	1	1	13
4	Surgical Oncology	1	1	13
5	Cancer Therapeutics	1	1	13

Pui Ying Chan

Publications

611

Citations

H-Index

Page 1

	Year	Citations
ctDNA monitoring using patient-specific sequencing and integration of variant reads Jonathan C. M. Wan, Katrin Heider, Davina Gale, Science Translational Medicine	2020	189
Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1–Deficient Thoracic Cancers Emma Beddowes, James Spicer, Pui Ying Chan, Journal of Clinical Oncology	2017	119
Clinical activity and safety of Pembrolizumab in Ipilimumab pre-treated patients with uveal melanoma Ioannis Karydis, Pui Ying Chan, Matthew Wheater, OncoImmunology	2016	87
The Novel Association of Circulating Tumor Cells and Circulating Megakaryocytes with Prostate Cancer Prognosis Lei Xu, Xueying Mao, Tianyu Guo, Clinical Cancer Research	2017	84
Noninvasive Detection of Clinically Significant Prostate Cancer Using Circulating Tumor Cells Lei Xu, Xueying Mao, Alistair Grey, The Journal of Urology	2019	40
A major responder to ipilimumab and nivolumab in metastatic uveal melanoma with concomitant autoimmunity Pui Ying Chan, Peter E. Hall, Gordon Hay, Pigment Cell & Melanoma Research	2017	36
A Phase 1 study of <scp>ADI‐PEG20</scp> (pegargiminase) combined with cisplatin and pemetrexed in <scp>ASS1‐negative</scp> metastatic uveal melanoma Pui Ying Chan, Melissa Phillips, Stephen Ellis, Pigment Cell & Melanoma Research	2022	26
Phase 1, pharmacogenomic, dose‐expansion study of pegargiminase plus pemetrexed and cisplatin in patients with ASS1‐deficient non‐squamous non‐small cell lung cancer Peter W. Szlosarek, Akhila Wimalasingham, Melissa Phillips, Cancer Medicine	2021	17
Curing Stage IV Melanoma: Where Have We Been and Where Are We? Pui Ying Chan, Pippa Corrie American Society of Clinical Oncology Educational Book Surgical OncologyImmunologyPathologyDermatologyImmunotherapy	2024	13

Page 1